Enrollment is closed. This study evaluates the efficacy of oral Copaxone in reducing relapse rates and new MRI lesions. Enrollment is closed. This trial will determine whether Copaxone is effective in slowing the progression of primary progressive multiple sclerosis. The study lasts three years and participants will receive annual MRI exams.
Enrollment is closed.
Zanaflex for Spasticity in MS and Spinal Cord Damage Study ongoing. Enrollment is closed. Trial will look at the effects of Zanaflex on spasticity and blood pressure. IFN reduced attacks and MRI lesions, yet had minimal effect on patients who had progression without concurrent attacks. Berlex Laboratories ATM-027 Antibody to T Cell Receptor Study was closed by sponsor before patient enrollment.